GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » RAMM Pharma Corp (XCNQ:RAMM) » Definitions » EV-to-EBIT

RAMM Pharma (XCNQ:RAMM) EV-to-EBIT : -0.06 (As of Jun. 24, 2025)


View and export this data going back to 2019. Start your Free Trial

What is RAMM Pharma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RAMM Pharma's Enterprise Value is C$0.91 Mil. RAMM Pharma's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 was C$-15.27 Mil. Therefore, RAMM Pharma's EV-to-EBIT for today is -0.06.

The historical rank and industry rank for RAMM Pharma's EV-to-EBIT or its related term are showing as below:

XCNQ:RAMM' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.5   Med: -1.02   Max: 0.26
Current: -0.06

During the past 7 years, the highest EV-to-EBIT of RAMM Pharma was 0.26. The lowest was -14.50. And the median was -1.02.

XCNQ:RAMM's EV-to-EBIT is ranked worse than
100% of 687 companies
in the Drug Manufacturers industry
Industry Median: 16.75 vs XCNQ:RAMM: -0.06

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. RAMM Pharma's Enterprise Value for the quarter that ended in Jan. 2025 was C$1.51 Mil. RAMM Pharma's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 was C$-15.27 Mil. RAMM Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2025 was -1,012.30%.


RAMM Pharma EV-to-EBIT Historical Data

The historical data trend for RAMM Pharma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RAMM Pharma EV-to-EBIT Chart

RAMM Pharma Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24
EV-to-EBIT
Get a 7-Day Free Trial -3.66 -5.68 -0.74 -0.16 -0.03

RAMM Pharma Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.29 -0.53 -0.13 -0.03 -0.10

Competitive Comparison of RAMM Pharma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, RAMM Pharma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RAMM Pharma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RAMM Pharma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RAMM Pharma's EV-to-EBIT falls into.


;
;

RAMM Pharma EV-to-EBIT Calculation

RAMM Pharma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.911/-15.274
=-0.06

RAMM Pharma's current Enterprise Value is C$0.91 Mil.
RAMM Pharma's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-15.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RAMM Pharma  (XCNQ:RAMM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

RAMM Pharma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2025 ) =EBIT / Enterprise Value (Q: Jan. 2025 )
=-15.274/1.508835
=-1,012.30 %

RAMM Pharma's Enterprise Value for the quarter that ended in Jan. 2025 was C$1.51 Mil.
RAMM Pharma's EBIT for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-15.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RAMM Pharma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of RAMM Pharma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


RAMM Pharma Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street E, Toronto, ON, CAN, M5C 1P1
RAMM Pharma Corp is engaged in the pharmaceutical and medical product business, including cannabinoid pharmacology and product formulation for cannabis-based pharmaceuticals and other cannabis-based products. The group generates revenue from the sale of medical devices and consumables, the sale of pharmaceutical products, and sale of cosmetics. Geographically, it derives a majority of its revenue from Uruguay.
Executives
Jackie Peter Burnett 10% Security Holder, Director, Senior Officer
Armando Gabriel Blankleider Director

RAMM Pharma Headlines

No Headlines